ArticleClinical and experimental vaccine research2026
Immunogenicity of anti-rabies vaccines (ARVs) marketed in Sri Lanka: a comparative study.
Article in Clinical and experimental vaccine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Several brands of anti-rabies vaccines (ARVs) are used for dog vaccination in Sri Lanka, which have shown major differences in their potency levels. This comparative study was conducted to determine humoral immune response of these ARVs using 2 different animal species. The reliability of an enzyme-linked immunosorbent assay (ELISA) antibody kit was assessed in comparison to the standard Fluorescent Antibody Virus Neutralization (FAVN) test. Materials and Methods: The laboratory animal study was conducted using 3-4 months old sero-negative New Zealand White rabbits. Nine vaccines from 7 producers were tested including 8 monovalent inactivated ARVs: Canvac R® single-dose and multi-dose, Nobivac® Rabies, Rabies Killed® Vaccine, Rabisin®, Defensor 3®, Raksharab® single-dose and multidose, and one bivalent inactivated ARV, Nobivac® RL. Second part was conducted in field dogs. Four vaccines with the highest potencies were selected for this field dog study. Animals were vaccinated subcutaneously with one dose of a selected ARV. Day 0 blood samples were collected just before the vaccination and Day 7, Day 14, and Day 30 samples from rabbits and Day 30 samples from dogs were collected post-vaccination. Results: Significant differences of humoral immune response between different vaccines brands were observed in both animal species. The coefficient of concordance between the FAVN test and the ELISA was 54.6% and 85.3% for rabbits and dogs respectively. Conclusion: The overall results showed that ARVs with proven potency can induce a robust humoral immune response following vaccination. There was a comparatively higher agreement between the FAVN test and the ELISA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.